4.7 Article

miR-204-3p/Nox4 Mediates Memory Deficits in a Mouse Model of Alzheimer's Disease

Journal

MOLECULAR THERAPY
Volume 29, Issue 1, Pages 396-408

Publisher

CELL PRESS
DOI: 10.1016/j.ymthe.2020.09.006

Keywords

-

Funding

  1. National Natural Science Foundation of China [81671055, 81971009, 81901091]
  2. Key Research and Development Program of Jiangsu Province of China [BE2016610]
  3. Jiangsu Province Key Medical Discipline Grant [ZDXKA2016020]
  4. Jiangsu Province Medical Youth Talent [QNRC2016024]
  5. Young Talent Support Program from Jiangsu Association for Science and Technology
  6. Canadian Institutes of Health Research Project [PJT-166127]

Ask authors/readers for more resources

The study showed that miR-204-3p attenuated memory deficits and oxidative stress in APP/PS1 mice by targeting Nox4, indicating that miR-204-3p overexpression and/or Nox4 inhibition could be a potential therapeutic strategy for AD treatment.
Alzheimer's disease (AD) is the most common neurodegenerative disorder leading to dementia in the elderly, and the mechanisms of AD are not fully defined. MicroRNAs (miRNAs) have been shown to contribute to memory deficits in AD. In this study, we identified that miR-204-3p was downregulated in the hippocampus and plasma of 6-month-old APPswe/PS1dE9 (APP/PS1) mice. miR-204-3p overexpression attenuated memory and synaptic deficits in APP/PS1 mice. The amyloid levels and oxidative stress were decreased in the hippocampus of APP/PS1 mice after miR-204-3p overexpression. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (Nox4) was a target of miR-204-3p, and Nox4 inhibition by GLX351322 protected neuronal cells against A beta(1-)(42)-induced neurotoxicity. Furthermore, GLX351322 treatment rescued synaptic and memory deficits, and decreased oxidative stress and amyloid levels in the hippocampus of APP/PS1 mice. These results revealed that miR-204-3p attenuated memory deficits and oxidative stress in APP/PS1 mice by targeting Nox4, and miR-204-3p overexpression and/or Nox4 inhibition might be a potential therapeutic strategy for AD treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available